NEW YORK (GenomeWeb) – Next-generation sequencing data firm OneOme has raised $1 million toward a targeted $5 million private financing round, it said in a document filed with the US Securities and Exchange Commission this week.
The company said 15 investors had participated in the round but did not disclose their identities. OneOme CEO Troy Kopischke told GenomeWeb that the financing is the firm's first seed round and will help it accelerate the growth of its pharmacogenomics platform.
The type of securities offered was in the form of options, warrants, or other rights to acquire another security, according to the company's SEC document.
OneOme was launched in September 2014 by the Mayo Clinic and biomedical investing firm Invenshure. It analyzes NGS data and reports on relevant pharmacogenomic information. At the time of its launch, the company said it would analyze patient NGS data generated within the Mayo Clinic, but eventually it planned to launch a broader service to other customers seeking pharmacogenomic-focused analysis and reporting of NGS results.